What is the treatment for hyperlipidemia?

Treatment of High Lipid Profile (Hyperlipidemia)

Initial Assessment and Classification

Begin with lifestyle modifications as the foundation for all patients with hyperlipidemia, while simultaneously determining which specific lipid abnormality requires pharmacologic intervention based on cardiovascular risk and lipid levels. 1

Before initiating any treatment, evaluate for secondary causes including:

• Uncontrolled diabetes mellitus (check HbA1c) 2
• Hypothyroidism (check TSH) 2
• Excessive alcohol intake 2
• Medications that raise lipids (thiazide diuretics, beta-blockers, estrogen therapy, corticosteroids, antiretrovirals, antipsychotics) 2
• Renal disease and liver disease 2

Obtain a complete fasting lipid panel to classify the dyslipidemia:

• LDL-C (primary target for most patients) 1
• Triglycerides (classify as normal <150, mild 150-199, moderate 200-499, severe 500-999, very severe ≥1000 mg/dL) 2
• HDL-C (goal >40 mg/dL in men, >50 mg/dL in women) 1
• Non-HDL-C (goal <130 mg/dL if triglycerides 200-499 mg/dL) 2

---

Lifestyle Modifications (Foundation for All Patients)

Dietary Interventions

For elevated LDL cholesterol:

• Reduce saturated fat to <7% of total calories 1, 2
• Eliminate trans fats to <1% of total calories 2
• Restrict dietary cholesterol to <200 mg/day 1, 2
• Increase soluble fiber to >10 g/day 2
• Add plant stanols/sterols 2 g/day 1, 2
• Limit total fat to 30-35% of calories 2

For elevated triglycerides (severity-based approach):

• Mild-moderate (150-499 mg/dL): Restrict added sugars to <6% of total calories, limit total fat to 30-35% 2
• Severe (500-999 mg/dL): Eliminate all added sugars completely, restrict fat to 20-25% of calories 2
• Very severe (≥1000 mg/dL): Extreme fat restriction to 10-15% of calories (or <5% until levels drop below 1000 mg/dL) 2

Weight Management and Physical Activity

• Target 5-10% weight loss, which produces approximately 20% reduction in triglycerides 2
• Engage in at least 150 minutes/week of moderate-intensity aerobic activity (or 75 minutes/week vigorous activity) 2
• Regular aerobic training decreases triglycerides by approximately 11% 2

Alcohol Restriction

• Complete abstinence is mandatory for severe hypertriglyceridemia (≥500 mg/dL) to prevent hypertriglyceridemic pancreatitis 2
• Limit or avoid alcohol for moderate hypertriglyceridemia 2

---

Pharmacologic Treatment Algorithm

Priority 1: Severe to Very Severe Hypertriglyceridemia (≥500 mg/dL)

Initiate fenofibrate immediately as first-line therapy to prevent acute pancreatitis, before addressing LDL cholesterol. 2, 3

• Start fenofibrate 54-160 mg daily with meals 3
• Fenofibrate reduces triglycerides by 30-50% 2
• Reassess lipid panel in 4-8 weeks 2
• Once triglycerides fall below 500 mg/dL, re-evaluate LDL-C and add statin if elevated or cardiovascular risk is high 2

Critical for diabetic patients: Aggressively optimize glycemic control first, as poor glucose control is often the primary driver of severe hypertriglyceridemia and may be more effective than additional medications 2

Priority 2: Elevated LDL Cholesterol (Primary Target for Most Patients)

For adults with diabetes aged ≥40 years or with other cardiovascular risk factors, initiate statin therapy regardless of baseline LDL levels. 1

Treatment goals:

• LDL-C <100 mg/dL (2.6 mmol/L) for most patients with diabetes 1
• LDL-C <70 mg/dL (1.8 mmol/L) for patients with overt cardiovascular disease (optional but preferred) 1

Statin selection:

• High-intensity statins (atorvastatin 40-80 mg or rosuvastatin 20-40 mg) provide ≥50% LDL-C reduction 2
• Moderate-intensity statins provide 30-50% LDL-C reduction 2
• Statins also provide 10-30% dose-dependent triglyceride reduction 1, 2

If LDL-C remains elevated after 3 months on maximally tolerated statin:

• Add ezetimibe 10 mg daily (provides additional 13-20% LDL-C reduction) 2
• Consider bile acid sequestrants (but avoid if triglycerides >200 mg/dL) 2

Priority 3: Moderate Hypertriglyceridemia (200-499 mg/dL) with Controlled LDL

If triglycerides remain 200-499 mg/dL after 3 months of optimized lifestyle modifications and statin therapy, add prescription omega-3 fatty acids. 2

• Icosapent ethyl 2-4 g/day (specifically indicated for patients with established cardiovascular disease OR diabetes with ≥2 additional risk factors on statin therapy) 2
• Provides 25% reduction in major adverse cardiovascular events 2
• Monitor for increased risk of atrial fibrillation 2

Alternative option:

• Fenofibrate 54-160 mg daily can be considered, but combination with statins increases myopathy risk 1, 2
• If combining fenofibrate with statin, use lower statin doses and monitor creatine kinase levels 1, 2

Priority 4: Low HDL Cholesterol (<40 mg/dL) with Controlled LDL

If HDL <40 mg/dL and LDL 100-129 mg/dL, consider gemfibrozil or niacin, especially if patient is intolerant to statins. 1

• Niacin 750-2,000 mg/day is most effective for raising HDL cholesterol 1
• At modest doses, niacin causes only modest glucose increases that are generally amenable to adjustment of diabetes therapy 1
• However, niacin showed no cardiovascular benefit when added to statin therapy in recent trials 2

---

Combination Therapy Considerations

Statin plus fibrate combination:

• Use fenofibrate rather than gemfibrozil when combining with statins (better safety profile) 1, 2
• Keep statin doses relatively low to minimize myopathy risk 1, 2
• Monitor creatine kinase levels and muscle symptoms, especially in patients >65 years or with renal disease 1, 2
• Note: The ACCORD trial showed no cardiovascular benefit from adding fenofibrate to statins in diabetic patients 2

Statin plus omega-3 fatty acids:

• Safer combination than statin plus fibrate 2
• Icosapent ethyl has proven cardiovascular benefit when added to statins 2

---

Special Populations

Patients with Diabetes

• Optimize glycemic control as highest priority, especially for severe hypertriglyceridemia 1, 2
• Target HbA1c <7% 2
• Insulin therapy (alone or with insulin sensitizers) may be particularly effective in lowering triglycerides 1

Patients with Renal Impairment

• Initiate fenofibrate at 54 mg/day in mild-moderate renal impairment 3
• Avoid fenofibrate in severe renal impairment or dialysis 3
• Adjust statin doses based on renal function 2

Elderly Patients (≥65 years)

• Base dose selection on renal function 3
• Increased myopathy risk with combination therapy 2
• Monitor more closely for adverse effects 2

---

Monitoring Strategy

Initial monitoring:

• Reassess fasting lipid panel in 4-8 weeks after initiating or adjusting therapy 2
• Check transaminases (AST/ALT) at baseline and periodically 2
• Monitor creatine kinase if using fibrates or combination therapy 2

Long-term monitoring:

• Once goals achieved, follow-up every 6-12 months 2
• Annual lipid panel if values at low-risk levels 1
• Consider reducing dosage if lipid levels fall significantly below targeted range 3

---

Critical Pitfalls to Avoid

• Do not delay fibrate therapy in patients with triglycerides ≥500 mg/dL while attempting lifestyle modifications alone—pharmacologic therapy is mandatory to prevent pancreatitis 2
• Do not start with statin monotherapy when triglycerides ≥500 mg/dL—statins provide only 10-30% triglyceride reduction, insufficient for preventing pancreatitis 2
• Do not combine gemfibrozil with statins—use fenofibrate instead due to lower myopathy risk 1, 2
• Do not use bile acid sequestrants if triglycerides >200 mg/dL—they can worsen hypertriglyceridemia 2
• Do not overlook secondary causes—uncontrolled diabetes, hypothyroidism, and medications must be addressed first 2
• Do not use over-the-counter fish oil as substitute for prescription omega-3 fatty acids—they are not equivalent 2